Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 327

1.

Non-viral delivery of RNA interference targeting cancer cells in cancer gene therapy.

Huang PI, Lo WL, Cherng JY, Chien Y, Chiou GY, Chiou SH.

Curr Gene Ther. 2012 Aug;12(4):275-84. Review.

PMID:
22856602
2.

RNA interference for the treatment of cancer.

Putral LN, Gu W, McMillan NA.

Drug News Perspect. 2006 Jul-Aug;19(6):317-24. Review.

PMID:
16971967
3.

TransKingdom RNA interference: a bacterial approach to challenges in RNAi therapy and delivery.

Keates AC, Fruehauf J, Xiang S, Li CJ.

Biotechnol Genet Eng Rev. 2008;25:113-27. Review.

PMID:
21412352
4.

Therapeutic potential of RNA interference against cancer.

Takeshita F, Ochiya T.

Cancer Sci. 2006 Aug;97(8):689-96. Review.

5.

In vivo application of RNA interference: from functional genomics to therapeutics.

Lu PY, Xie F, Woodle MC.

Adv Genet. 2005;54:117-42. Review.

PMID:
16096010
6.

Efficient and targeted delivery of siRNA in vivo.

Shim MS, Kwon YJ.

FEBS J. 2010 Dec;277(23):4814-27. doi: 10.1111/j.1742-4658.2010.07904.x. Review.

7.
8.

Therapeutic siRNA: principles, challenges, and strategies.

Gavrilov K, Saltzman WM.

Yale J Biol Med. 2012 Jun;85(2):187-200. Epub 2012 Jun 25. Review.

9.

Cationic lipids and polymers mediated vectors for delivery of siRNA.

Zhang S, Zhao B, Jiang H, Wang B, Ma B.

J Control Release. 2007 Oct 18;123(1):1-10. Epub 2007 Aug 7. Review.

PMID:
17716771
10.

RNA interference advances to early-stage clinical trials.

Brower V.

J Natl Cancer Inst. 2010 Oct 6;102(19):1459-61. doi: 10.1093/jnci/djq405. Epub 2010 Sep 24. No abstract available.

PMID:
20870977
11.

[Current status of non-viral vectors for siRNA delivery].

Yang FF, Huang W, Li YF, Gao ZG.

Yao Xue Xue Bao. 2011 Dec;46(12):1436-43. Review. Chinese.

PMID:
22375415
12.

Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications.

Huang C, Li M, Chen C, Yao Q.

Expert Opin Ther Targets. 2008 May;12(5):637-45. doi: 10.1517/14728222.12.5.637 . Review.

PMID:
18410245
13.

Advances in liver-directed gene therapy for hepatocellular carcinoma by non-viral delivery systems.

Ding B, Li T, Zhang J, Zhao L, Zhai G.

Curr Gene Ther. 2012 Apr 1;12(2):92-102. Review.

PMID:
22348553
14.

Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies.

Deng Y, Wang CC, Choy KW, Du Q, Chen J, Wang Q, Li L, Chung TK, Tang T.

Gene. 2014 Apr 1;538(2):217-27. doi: 10.1016/j.gene.2013.12.019. Epub 2014 Jan 7. Review.

PMID:
24406620
15.

Nanoparticle-based delivery system for application of siRNA in vivo.

Wang Y, Li Z, Han Y, Liang LH, Ji A.

Curr Drug Metab. 2010 Feb;11(2):182-96. Review.

PMID:
20359287
16.

Intravenous, non-viral RNAi gene therapy of brain cancer.

Pardridge WM.

Expert Opin Biol Ther. 2004 Jul;4(7):1103-13. Review.

PMID:
15268677
17.

RNAi in functional genomics.

Scherr M, Eder M.

Curr Opin Mol Ther. 2004 Apr;6(2):129-35. Review.

PMID:
15195923
18.

Small RNAs and non-small cell lung cancer.

Tong AW.

Curr Mol Med. 2006 May;6(3):339-49. Review.

PMID:
16712479
19.

Future prospect of RNA interference for cancer therapies.

Ashihara E, Kawata E, Maekawa T.

Curr Drug Targets. 2010 Mar;11(3):345-60. Review.

PMID:
20210759
20.

In vivo gene delivery by nonviral vectors: overcoming hurdles?

Zhang Y, Satterlee A, Huang L.

Mol Ther. 2012 Jul;20(7):1298-304. doi: 10.1038/mt.2012.79. Epub 2012 Apr 24. Review.

Supplemental Content

Support Center